ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2135

Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis

James C Waddington1, Ruoyi Zhou1, Orla Coleman1, Bruna Wundervald2, Andrew Parnell3, Vinod Chandran4, Lara Fallon5, Douglass Chapman6, Remy Pollock7, Shibing Deng8, Oliver FitzGerald9, Stephen R Pennington10 and Philip J Mease11, 1Atturos, Dublin, Ireland, 2Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, 3Hamilton Institute, Maynooth University, Kildare, Ireland, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, New York, NY, 7Pfizer Canada ULC, Kirkland QC, Canada, 8Pfizer Inc, Waterford, MI, 9Conway Institute, University College Dublin, Dublin, Ireland, 10Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Biomarkers, proteomics, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Session Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM] and unbiased discovery) for analysis of baseline (BL) serum samples from patients (pts) with PsA receiving tofacitinib, adalimumab (ADA), or placebo (PBO), 181 candidate biomarker peptides were identified that may predict treatment response in PsA.3 We evaluated an updated, quantitative MRM assay that incorporated the differentially expressed peptides previously found and assessed its ability to predict treatment response.

Methods: Pts with PsA receiving tofacitinib 5 or 10 mg twice daily, ADA, or PBO in OPAL Broaden (NCT01877668)1 were classed as responders (R) or non-R (NR) by Month 3 PsA Disease Activity Score (R: lowest score ≤ 3.2; NR: highest score > 3.2). BL serum samples were analyzed via an updated targeted MS MRM assay, including peptides representing the proteins previously identified as differentially expressed in R vs NR serum samples using MRM analysis of an in-house panel (‘PAPRICA’) and unbiased discovery liquid chromatography-tandem MS (LC‑MS/MS). Peptide data quality was examined manually; low signal:noise ratio (< 6) and/or poor peak shape identified those not meeting quality assessment. PAPRICA data were normalized to (1) stable isotopically labeled (SIL) peptide spike-ins and (2) an endogenous peptide panel representing total serum protein abundance (TSPA). Univariate analyses (Student’s t-test with no multiplicity adjustment) and multivariate machine learning Random Forest (RF) modeling4 were performed.

Results: In quality control, 40 peptides were removed due to low signal:noise ratio and/or poor peak shape. Univariate analysis identified 41 peptides (34 from PAPRICA; 7 from LC-MS/MS) differentially expressed (p £ 0.05) in R (N=47) vs NR (N=49). In all, 21/9/13 peptides were differentially expressed in the tofacitinib/ADA/PBO groups (Fig 1a). The 41 peptides mapped to 29 unique proteins (16/8/8 differentially expressed in the tofacitinib/ADA/PBO groups; Fig 1b). RF analysis generated models with a modest ability to predict treatment response; performance was broadly equivalent to PAPRICA3 (Fig 2). These models, made up of 6/12/14 variables from the raw/SIL normalized/TSPA normalized datasets, mostly contained peptides originally identified in PAPRICA; 2 peptides per model were identified in LC-MS/MS (Fig 3).

Conclusion: Analysis of an updated panel of candidate biomarkers for predicting treatment response in pts with PsA identified 41 differentially expressed peptides from 29 proteins associated with R vs NR to tofacitinib, ADA, or PBO. RF models had a modest ability to predict BL treatment response. Further evaluation is ongoing to verify these candidate predictors of response, and we will report how these proteins map to biologic processes, pathways, and networks.

1. Mease et al. N Engl J Med 2017; 377: 1537-50
2. Gladman et al. N Engl J Med 2017; 377: 1525-36
3. Waddington et al. Ann Rheum Dis 2022; 81 (S1): 840
4. Breiman. Mach Learn 2001; 45: 5-32

Study sponsored by Pfizer. Medical writing support was provided by J Bardos, CMC Connect, and funded by Pfizer.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Waddington, Atturos; R. Zhou, Atturos; O. Coleman, Atturos; B. Wundervald, Atturos; A. Parnell, None; V. Chandran, AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Amgen, Pfizer Inc, UCB; L. Fallon, Pfizer Inc; D. Chapman, Pfizer Inc; R. Pollock, Pfizer Inc; S. Deng, Pfizer Inc; O. FitzGerald, Novartis, UCB, Bristol-Myers Squibb(BMS), Pfizer Inc, Eli Lilly, AbbVie, Janssen; S. Pennington, None; P. Mease, AbbVie, Amgen, Janssen, Novartis, Pfizer Inc, UCB, Sun Pharma, Eli Lilly, Bristol-Myers Squibb(BMS), Celgene, Genentech.

To cite this abstract in AMA style:

Waddington J, Zhou R, Coleman O, Wundervald B, Parnell A, Chandran V, Fallon L, Chapman D, Pollock R, Deng S, FitzGerald O, Pennington S, Mease P. Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-candidate-protein-biomarkers-to-predict-treatment-response-in-patients-with-psoriatic-arthritis/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-candidate-protein-biomarkers-to-predict-treatment-response-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences